AI Article Synopsis
- Excessive zinc intake can lead to copper deficiency, which is often overlooked as a cause of anemia in patients with end-stage renal disease (ESRD).
- A case study highlighted an ESRD patient who suffered from anemia resistant to erythropoietin (EPO) treatment after receiving too much zinc; even extensive tests initially failed to identify the issue.
- Stopping the zinc supplement and starting copper replacement therapy successfully restored the patient's EPO effectiveness, emphasizing the need for awareness of zinc-induced copper deficiency in similar cases.
Article Abstract
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can result in erythropoietin (EPO)-resistant anemia and may not be considered as a possible etiology when conducting the work-up. We present a case wherein an ESRD patient had been receiving excess zinc for several months and subsequently experienced EPO-resistant anemia. Our patient's GI work-up was negative, and increased doses of iron and EPO-stimulating agent were ineffective. She underwent a bone marrow biopsy and more serological testing. She was ultimately diagnosed with ZICD, and cessation of her zinc supplement and initiation of copper replacement proved effective in restoring EPO responsiveness. Awareness of ZICD as a possible factor in EPO-resistant anemia could lead to an expedited diagnosis and avoid an unnecessary and extensive work-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299384 | PMC |
| http://dx.doi.org/10.1159/000512612 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Roxadustat for Patients with Posttransplant Anemia: A Narrative Review.
Kidney Dis (Basel)
February 2024
Department of Nephrology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in China, Japan, South Korea, Chile, and Europe. Roxadustat is involved in HIF degradation, which can stimulate endogenous erythropoietin (EPO) production and improve iron utilization.
View Article and Find Full Text PDFThrombopoietin treats erythropoietin resistance by correcting EPO-induced progenitorcell depletion.
Biochem Pharmacol
February 2024
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address:
Recombinant human erythropoietin (rHuEPO) is a prevalent treatment for anemia in patients with chronic kidney disease. However, up to 10% of these patients exhibit EPO resistance or hyporesponsiveness, which may be caused by the depletion of erythroid progenitor cells. Thrombopoietin (TPO) has the potential to promote the growth of early progenitor cells and correct the depletion.
View Article and Find Full Text PDFA Novel Combination Therapy of Erythropoietin and Thrombopoietin to Treat Erythropoietin-Resistance anemia.
Pharm Res
June 2022
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR.
Purpose: Treatment with recombinant human erythropoietin (rHuEPO) may correct anemia in patients with chronic kidney disease. However, up to 10% of these patients exhibit EPO resistance or hyporesponsiveness, which may be caused by the depletion of erythroid progenitor cells. Thrombopoietin (TPO) stimulates the self-renewal of stem cells and promotes the growth of early erythroid progenitor cells.
View Article and Find Full Text PDFFate Determination Role of Erythropoietin and Romiplostim in the Lineage Commitment of Hematopoietic Progenitors.
J Pharmacol Exp Ther
July 2022
School of Pharmacy (X.F., X.Y.) and Division of Hematology, Department of Medicine and Therapeutics (R.S.M.W.), Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong; and Department of Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York (W.K.)
Erythropoietin (EPO) and thrombopoietin (TPO) have long been known to promote erythropoiesis and megakaryopoiesis, respectively. However, the fate-changing role of EPO and TPO on megakaryocyte-erythroid progenitors (MEPs) to develop along the erythroid versus megakaryocyte lineage remains unclear. We have previously shown that EPO may have a fate-changing role because EPO treatment could induce progenitor cells depletion and result in EPO resistance.
View Article and Find Full Text PDFErythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Case Rep Nephrol Dial
July 2021
East Georgia Kidney and Hypertension, Augusta, Georgia, USA.
Article Synopsis
- Excessive zinc intake can lead to copper deficiency, which is often overlooked as a cause of anemia in patients with end-stage renal disease (ESRD).
- A case study highlighted an ESRD patient who suffered from anemia resistant to erythropoietin (EPO) treatment after receiving too much zinc; even extensive tests initially failed to identify the issue.
- Stopping the zinc supplement and starting copper replacement therapy successfully restored the patient's EPO effectiveness, emphasizing the need for awareness of zinc-induced copper deficiency in similar cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!